BioNet has been supporting institutes and manufacturers, in particular from Asian and African countries, to build up capacity in vaccine R&D and production, through public and private partnerships of all kinds, ranging from technology transfer to joint-development. Quality, service, trust, innovation and technical excellence are embedded in every venture we undertake.

Over the years, BioNet has created unprecedented Product Development Partnerships fostering vaccine self-reliance and leading to:


Most recently BioNet has obtained licensure for its two innovative recombinant acellular pertussis vaccines in Thailand, including Pertagen® the only monovalent recombinant pertussis vaccine approved for adolescents and adults.